CHSY1 promoted proliferation and suppressed apoptosis in colorectal cancer through regulation of the NFκB and/or caspase‑3/7 signaling pathway

Zeng,Lifeng; Qian,Jinrong; Luo,Xiaojiang; Zhou,Aiqun; Zhang,Zhiyong; Fang,Quangang

doi:10.3892/ol.2018.9385

CHSY1 promoted proliferation and suppressed apoptosis in colorectal cancer through regulation of the NFκB and/or caspase‑3/7 signaling pathway

Authors:
- Lifeng Zeng
- Jinrong Qian
- Xiaojiang Luo
- Aiqun Zhou
- Zhiyong Zhang
- Quangang Fang
View Affiliations

Affiliations: Department of Clinical Laboratory, Jiangxi Province People's Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Health Care of Cadre, Jiangxi Province People's Hospital, Nanchang, Jiangxi 330006, P.R. China, Department of Gastrointestinal Surgery, Jiangxi Province People's Hospital, Nanchang, Jiangxi 330006, P.R. China
Published online on: September 3, 2018 https://doi.org/10.3892/ol.2018.9385
Pages: 6140-6146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is a commonly observed malignant cancer. However, the limited therapies for colorectal cancer do not bring much benefit for patients. Chondroitin synthase‑1 (CHSY1) is an enzyme responsible for the biosynthesis of chondroitin sulfate and has been implicated in the tumorigenesis of several cancer types; however, there is limited information regarding the role of CHSY1 in colorectal cancer. In the present study, CHSY1 was demonstrated to be highly expressed in colorectal cancer tissues and in cell lines, and the CHSY1 expression level was associated with the 5‑year survival rate of patients with colorectal cancer. Following CHSY1 knockdown, the proliferation of colorectal cancer cells was significantly decreased. The number of RKO cells decreased by 50% following CHSY1 knockdown compared with that in the control after culture for 5 days. However, the apoptosis rate of RKO cells increased to 14.15% after CHSY1 knockdown. In addition, the activity of caspase‑3/7 was also enhanced. Furthermore, the expression of B‑cell lymphoma 2 (Bcl‑2) was reduced, whereas the levels of Bcl‑2‑associated X protein (Bax) and truncated caspase‑3/7 were increased following CHSY1 knockdown. Additionally, the phosphorylation level of IκB and the expression of nuclear factor (NF)κB also decreased. In contrast, forced expression of CHSY1 increased the level of Bcl‑2, NFκB, and phosphorylated IκB, whereas the level of bax and truncated caspase‑3/7 decreased. Therefore, the data of the present study suggest that CHSY1 promoted cell proliferation by regulating NFκB signaling and suppressed cell apoptosis by regulating/caspase‑3/7 signaling in colorectal cancer. The present study also suggests that CHSY1 may be a potential target for colorectal cancer therapy.

View Figures

View References

1	Martel-Pelletier J, Boileau C, Pelletier JP and Roughley PJ: Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 22:351–384. 2008. View Article : Google Scholar : PubMed/NCBI
2	Holmborn K, Habicher J, Kasza Z, Eriksson AS, Filipek-Gorniok B, Gopal S, Couchman JR, Ahlberg PE, Wiweger M, Spillmann D, et al: On the roles and regulation of chondroitin sulfate and heparin sulfate in zebrafish pharyngeal cartilage morphogenesis. J Biol Chem. 287:33905–33916. 2012. View Article : Google Scholar : PubMed/NCBI
3	Winship A, Van Sinderen M, Heffernan-Marks A and Dimitriadis E: Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration. Int J Oncol. 50:798–804. 2017. View Article : Google Scholar : PubMed/NCBI
4	du Souich P, García AG, Vergés J and Montell E: Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 13:1451–1463. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS and Vynios DH: Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: Structural and expressional studies. Oncol Rep. 22:369–375. 2009.PubMed/NCBI
6	Ogawa H, Hatano S, Sugiura N, Nagai N, Sato T, Shimizu K, Kimata K, Narimatsu H and Watanabe H: Chondroitin sulfate synthase-2 is necessary for chain extension of chondroitin sulfate but not critical for skeletal development. PLoS One. 7:e438062012. View Article : Google Scholar : PubMed/NCBI
7	Hashimoto SI, Ogoshi K, Sasaki A, Abe J, Qu W, Nakatani Y, Ahsan B, Oshima K, Shand FH, Ametani A, et al: Coordinated changes in DNA methylation in antigen-specific memory CD4 T cells. J Immunol. 190:4076–4091. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wilson DG, Phamluong K, Lin WY, Barck K, Carano RA, Diehl L, Peterson AS, Martin F and Solloway MJ: Chondroitin sulfate synthase 1 (Chsy1) is required for bone development and digit patterning. Dev Biol. 363:413–425. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Laue K, Temtamy S, Aglan M, Kotan LD, Yigit G, Canan H, Pawlik B, Nürnberg G, Wakeling EL, et al: Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling. Am J Hum Genet. 87:757–767. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yin L: Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions. J Biol Chem. 280:15666–15672. 2005. View Article : Google Scholar : PubMed/NCBI
11	Momose T, Yoshimura Y, Harumiya S, Isobe K, Kito M, Fukushima M, Kato H and Nakayama J: Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance. Hum Pathol. 50:15–23. 2016. View Article : Google Scholar : PubMed/NCBI
12	Tian J, Ling L, Shboul M, Lee H, O'Connor B, Merriman B, Nelson SF, Cool S, Ababneh OH, Al-Hadidy A, et al: Loss of CHSY1, a secreted FRINGE enzyme, causes syndromic brachydactyly in humans via increased NOTCH signaling. Am J Hum Genet. 87:768–778. 2010. View Article : Google Scholar : PubMed/NCBI
13	Liu CH, Lan CT, Chou JF, Tseng TJ and Liao WC: CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway. Cancer Lett. 403:280–288. 2017. View Article : Google Scholar : PubMed/NCBI
14	Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS and Vynios DH: Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Rep. 4:363–368. 2011.PubMed/NCBI
15	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
16	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
17	Pabla B, Bissonnette M and Konda VJ: Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol. 6:133–141. 2015. View Article : Google Scholar : PubMed/NCBI
18	Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI
19	Luo Y, Tsuchiya KD II, Park D, Fausel R, Kanngurn S, Welcsh P, Dzieciatkowski S, Wang J and Grady WM: RET is a potential tumor suppressor gene in colorectal cancer. Oncogene. 32:2037–2047. 2013. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Fisher R, Pusztai L and Swanton C: Cancer heterogeneity: Implications for targeted therapeutics. Br J Cancer. 108:479–485. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
23	Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, He YL, Chen D and Li W: MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med. 12:332014. View Article : Google Scholar : PubMed/NCBI
24	Cui H, Yuan J, Du X, Wang M, Yue L and Liu J: Ethyl gallate suppresses proliferation and invasion in human breast cancer cells via Akt-NF-κB signaling. Oncol Rep. 33:1284–1290. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li F, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: NF-κB in cancer therapy. Arch Toxicol. 89:711–731. 2015. View Article : Google Scholar : PubMed/NCBI
26	Makin G and Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res. 301:143–152. 2000. View Article : Google Scholar : PubMed/NCBI
27	Dandekar DS, Lopez M, Carey RI and Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and −9 in prostate cancer cells. Int J Cancer. 115:484–492. 2005. View Article : Google Scholar : PubMed/NCBI
28	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
29	Vermeulen K, Van Bockstaele DR and Berneman ZN: Apoptosis: Mechanisms and relevance in cancer. Ann Hematol. 84:627–639. 2005. View Article : Google Scholar : PubMed/NCBI